Lilly developing biotech drugs the old-fashioned way

Pharma's biotech strategy is pretty clear: Buy companies or license in drugs and technology to get a leg up in the expanding market. But The Wall Street Journal notes that Eli Lilly has taken its own unusual approach--developing new biotech therapies from scratch. That's a slow approach, and one that is likely to take years to prove, or disprove, its utility. Half of Lilly's drugs entering the pipeline this year are biotech drugs, up from 10 percent in 2001. And by 2011, Lilly says it will introduce one new biotech drug each year.

- read The Wall Street Journal's article on Lilly (sub. req.)

Related Articles:
Buyouts a sign of industry's health. Report
The Top 5 Buyouts of 2007. Report
Deals and more deals. Report
Lilly buying Icos in $2.1B deal. Report

Suggested Articles

Galecto picked up $64 million to push its lead lung disease treatment toward an approval in Europe and fund midstage studies for its other programs.

The financing, which attracted support from Roche Venture Fund, sets Palladio up to test its vasopressin V2 receptor antagonist in a kidney disease.

A new atlas of 500,000 cardiac cells could help researchers better understand how a healthy heart operates—and what goes wrong in heart disease.